Zhang Jun, Director of the Oncology Department at Ruijin Hospital, in collaboration with our research group, designed and initiated a “basket” clinical trial using arsenic trioxide to treat p53 mutant cancer patients
The European Anti Cancer Foundation TP53 Trust and the International Clinical Research Organization REDO have invited Researcher Lu Min to explore the feasibility, risk benefit ratio, and open discussion of intermittent low-dose arsenic dosing for the prevention and treatment of p53 congenital mutation related cancers in the patient population
The research achievements of the research team, together with the other nine events, such as the overseas approval of the domestic COVID-19 vaccine and the promulgation of the Chinese Pharmacopoeia, were rated as the top ten pharmaceutical events in China in 2020 by the Journal of Pharmacy
Research on Targeted Drugs for Heavy Cancer Treatment Targets
In China, how many years can one live on average after getting these cancers?
What are the most common and deadly types of cancer in China?
How many new cases and deaths of cancer have occurred in China in the past 10 years?
What is the probability of developing cancer in a person’s lifetime?
Tang Yigang, a member of Lu Min’s research group, completed the defense of his doctoral thesis
Researcher Lu Min served as the executive chair of the Youth Forum at the 18th National Congress of Experimental Hematology and delivered a keynote speech on “Targeting the Tumor Suppressor Protein p53.”
Experimental Hematology (CSEH), chairing the conference and giving an oral talk